Compare PAGSEG Inc (PAGS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Pfizer Inc — how do they compare? PAGSEG Inc trades at $10.65 (market cap $2.90B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 55× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.66%). Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 26 Days and Pfizer Inc for 158 Days on average.
| PAGS | PFE | |
|---|---|---|
Market Cap | $2.90B | $159.59B |
Volume | 4,931,855 | 30,937,010 |
Sector | Industrials | Health |
52-Week High | $12.00 | $29.02 |
52-Week Low | $8.44 | $23.67 |
Typical Hold Time | 26 Days | 158 Days |
Enterprise Value | $11.04B | $211.09B |
Dividend Yield | 10.66% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7 and net income margin of 10.45%, supported by recent earnings beats. A dividend of $0.28 is scheduled for September 2026. Analyst consensus is bullish with a $10.70 price target, though RSI levels indicate potential overbought conditions near-term.
The outlook for PAGS is positive given its undervalued metrics and profitability, but risks include macroeconomic pressures in Brazil and elevated credit losses. Institutional interest remains strong, with recent buys from Bank of America. The stock presents a value opportunity with dividend income, though investors should monitor earnings consistency and interest rate impacts.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
